Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
2026年 9月 29日
Read MoreZai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
2026年 8月 6日
Read MoreU.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
2026年 8月 3日
Read MoreZai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
2026年 7月 22日
Read MoreZai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
2026年 6月 16日
Read MoreZai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
2026年 6月 8日
Read MoreZai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs) - TC
2026年 5月 11日
Read More